Dupilumab Treatment in Atopic Dermatitis: Real-World Evidence from a Portuguese Tertiary Center
Introduction: Dupilumab is a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, key drivers of type 2 helper T-cell (Th2)-mediated inflammatory response. It was the first biologic treatment approved for adult patients with inadequately-controlled moderate-to-severe atopic...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Portuguesa de Dermatologia e Venereologia
2021-06-01
|
| Series: | Revista da Sociedade Portuguesa de Dermatologia e Venereologia |
| Subjects: | |
| Online Access: | https://revista.spdv.com.pt/index.php/spdv/article/view/1318 |